• Home
  • About us
  • Team
    • Management team
    • Advisory Board
  • Portfolio companies
    • Exited investments
    • Current investments
  • News
  • Contact

News

Home / News

Immusoft and Takeda Collaborate to Discover and Develop Cell Therapies for Rare Neurometabolic Disorders

13.10.2021

Immusoft’s Immune System Programming (ISP™) technology platform has been designed to address the challenges associated with current cell therapies

More

Pipeline Therapeutics Appoints Scott Oross as General Counsel

25.06.2021

SAN DIEGO, June 25, 2021 – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced that Scott Oross has been appointed as General Counsel.

More

Immusoft Announces Formation Of Scientific Advisory Board

23.06.2021

SEATTLE–Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs.

More

PanDx raises seed investment to develop a versatile catheter to treat severe GI conditions

25.12.2020

RBV Capital (backed by Alexey Repik’s R-Pharm and RVC) invested RUB 105 million (ca. $1.5M) in PanDx, a UK-based company developing a novel catheter to treat acute pancreatitis and other severe conditions of the gastrointestinal tract (GI).

More

Botkin.AI raises $2M to further develop its medical AI platform

23.12.2020

Intellogic LLC, raised 160M rubles (ca $2M) in its Series B investment round to further develop its artificial intelligence platform for the analysis of medical images, Botkin.AI.

More
Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11